Safinamide is a selective, reversible monoamine oxidase B (MAO-B) inhibitor used as an adjunct therapy with levodopa and carbidopa in the treatment of Parkinson's disease (PD). It helps reduce "off" episodes, where Parkinson's symptoms return as the effects of levodopa wear off. In addition to MAO-B inhibition, safinamide also modulates glutamate release, which may contribute to its therapeutic benefits.
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
![(S)-2-[4-(3-Fluorobenzyloxy) benzylamino]propionic Acid Methyl Ester](https://veeprho.com/wp-content/uploads/2023/01/S-2-4-3-Fluorobenzyloxy-benzylamino-propionic-acid-methyl-ester.png "(S)-2-[4-(3-Fluorobenzyloxy) benzylamino]propionic Acid Methyl Ester")
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
Parent: Safinamide
![4-[(3-Fluorobenzyl)oxy]benzoic Acid](https://veeprho.com/wp-content/uploads/2023/01/4-3-Fluorobenzyl-oxy-benzoic-Acid.png "4-[(3-Fluorobenzyl)oxy]benzoic Acid")
Parent: Safinamide
During the manufacturing and storage of safinamide, impurities may form that must be controlled to ensure safety, efficacy, and stability.
Related Substances
These are structurally similar compounds that may form during synthesis or degradation. Controlling these impurities is crucial for maintaining the drug’s pharmacological activity.
Degradation Products
Safinamide is susceptible to oxidative degradation, leading to potential formation of inactive or toxic byproducts. Proper storage conditions help minimize degradation.
Residual Solvents
Trace amounts of solvents used in synthesis or formulation may remain in the final product. Regulatory guidelines set acceptable limits to ensure they do not pose a health risk.
Analytical Techniques for Impurity Detection
Methods such as High-Performance Liquid Chromatography (HPLC) and Gas Chromatography-Mass Spectrometry (GC-MS) are used to monitor impurities and maintain high purity standards.
Yes, safinamide is a selective, reversible MAO-B inhibitor, which increases dopamine levels in the brain by preventing its breakdown. This helps improve motor symptoms in Parkinson’s disease.
Safinamide is generally well-tolerated, but it may cause side effects such as nausea, insomnia, and dyskinesia. It should be used with caution in patients with severe liver impairment.
Safinamide is usually taken once daily, with or without food. It is best taken at the same time each day to maintain consistent therapeutic levels.
Safinamide works by inhibiting MAO-B, an enzyme responsible for breaking down dopamine. Additionally, it modulates glutamate release, providing further neuroprotective effects and symptom relief in Parkinson’s disease.
